Radiolabeling of zoledronic acid with 188Re as a new palliative agent radiotracer in treatment of bone tumors

  • Mostafa Erfani
  • Mina Tabatabaei
  • Alireza Doroudi
  • Mohammad Shafiei


Zoledronic acid is a bisphosphonates to treat bone problems. Rhenium-188-zoledronic acid could be used as a palliate agent in skeletal metastases. Radiolabeled product was prepared through optimized radiochemical procedures. The organs uptake especially bone uptake assessed in healthy animals mice. The radiochemical purity of the radiotracer was > 95% which was stable up to 24 h. Bone uptake (1.08 ± 0.14% ID/g at 1 h) with retention of activity in bone up to 24 h (0.26 ± 0.06% ID/g) was reached. This radiotracer can be used as a developing candidate for a palliative treatment of bone metastasis.


188Re-ZNA Zolendronic acid Radiotracer Palliative Skeletal metastases 



We like to appreciate Mr. Pezham for providing sodium perrehenate and help through animal study.


  1. 1.
    Vincent J, Vigorita MD (2007) Cancer-principles and practice of oncology. Lippincott, Williams & Wilkins, Philadelphia, pp 2713–2729Google Scholar
  2. 2.
    Mundy GR (2002) Metastasis: metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2(8):584–593CrossRefGoogle Scholar
  3. 3.
    Mantyh PW (2014) The neurobiology of skeletal pain. Eur J Neurosci 39:508–519CrossRefGoogle Scholar
  4. 4.
    Diel IJ (2006) What do patients with metastatic bone pain need? Eur J Cancer Suppl 4(8):1–3CrossRefGoogle Scholar
  5. 5.
    Moos R, Costa L, Ripamonti CI, Niepel D, Santini D (2017) Improving quality of life in patients with advanced cancer: targeting metastatic bone pain. Eur J Cancer 71:80–94CrossRefGoogle Scholar
  6. 6.
    Sartor O, Hoskin P, Bruland ØS (2013) Targeted radio-nuclide therapy of skeletal metastases. Cancer Treat Rev 39:18–26CrossRefGoogle Scholar
  7. 7.
    Iwamoto J, Takeda T, Ichimura S (2002) Transient relief of metastatic cancer bone pain by oral administration of etidronate. J Bone Miner Metab 20(4):228–234CrossRefGoogle Scholar
  8. 8.
    Green JR (2004) Bisphosphonates: preclinical review. Oncologist 9(Suppl 4):3–13CrossRefGoogle Scholar
  9. 9.
    Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO (2003) Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 21(23):4277–4284CrossRefGoogle Scholar
  10. 10.
    Vitale G, Fonderico F, Martignetti A, Caraglia M, Ciccarelli A, Nuzzo V, Bbruzzese A, Lupoli G (2001) Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. Br J Cancer 84(12):1586–1590CrossRefGoogle Scholar
  11. 11.
    Tripathy D, Lichinitzer M, Lazarev A, MacLachlan SA, Apffelstaedt J, Budde M, Bergstrom B (2004) Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann Oncol 15(5):743–750CrossRefGoogle Scholar
  12. 12.
    Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D (2005) Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease. N Engl J Med 353(9):898–908CrossRefGoogle Scholar
  13. 13.
    Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, Watanabe T, Goessl C, Ohashi Y, Takashima S (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23(15):3314–3321CrossRefGoogle Scholar
  14. 14.
    Wardley A, Davidson N, Barrett-Lee P, Hong A, Mansi J, Dodwell D, Murphy R, Mason T, Cameron DW (2005) Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 92(10):1869–1876CrossRefGoogle Scholar
  15. 15.
    Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7(5):377–387Google Scholar
  16. 16.
    Lange R, Ter Heine R, Knapp RF, de Klerk JM, Bloemendal HJ, Hendrikse NH (2016) Pharmaceutical and clinical development of phosphonate-based radiopharmaceuticals for the targeted treatment of bone metastases. Bone 91:159–179CrossRefGoogle Scholar
  17. 17.
    Hoskin P, Sartor O, O’Sullivan JM, Johannessen DC, Helle SI, Logue J, Bottomley D, Nilsson S, Vogelzang NJ, Fang F, Wahba M, Aksnes AK, Parker C (2014) Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 5ALSYMPCA6 trial. Lancet Oncol 15(12):1397–1406CrossRefGoogle Scholar
  18. 18.
    Morris MJ, Sartor O, Vogelzang NJ, Shore ND, Cislo P, Bangerter K, Sweeney C (2015) Effect of radium-223 dichloride (Ra-223) on pain from US EAP. J Clin Oncol 33:A160CrossRefGoogle Scholar
  19. 19.
    Pandit-Taskar N, Batraki M, Divgi CR (2004) Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med 45:1358–1365Google Scholar
  20. 20.
    Pillai MRA, Dash A, Knapp FF (2012) Rhenium-188: availability from the 188W/188Re generator and status of current applications. Curr Radiopharm 5:228–243CrossRefGoogle Scholar
  21. 21.
    Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ, Coleman RE, Kotler JA, Freeman LM, Olivier P (2004) Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 63:940–945CrossRefGoogle Scholar
  22. 22.
    Das T, Shinto A, Karuppuswamy Kamaleshwaran K, Banerjee S (2016) Theranostic treatment of metastatic bone pain with 177Lu-DOTMP. Clin Nucl Med 41(12):966–967CrossRefGoogle Scholar
  23. 23.
    Baum RP, Kulkarni HR (2012) THERANOSTICS: from molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy-the bad berka experience. Theranostics 2:437–447CrossRefGoogle Scholar
  24. 24.
    Paes FM, Serafini AN (2010) Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain in Seminars in nuclear medicine. Semin Nucl Med 40(2):89–104CrossRefGoogle Scholar
  25. 25.
    Argyrou M, Valassi A, Andreou M, Lyra M (2013) Rhenium-188 production in hospitals, by W-188/Re-188 generator, for easy use in radionuclide therapy. Int J Mol Imaging 2013:290750CrossRefGoogle Scholar
  26. 26.
    Liepe K, Kropp J, Runge R, Kotzerke J (2003) Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases. Br J Cancer 89(4):625–629CrossRefGoogle Scholar
  27. 27.
    Meckel M, Bergmann R, Miederer M, Roesch F (2016) Bone targeting compounds for radiotherapy and imaging: *Me(III)-DOTA conjugates of bisphosphonic acid, pamidronic acid and zoledronic acid. EJNMMI Radiophar Chem 1(1):14CrossRefGoogle Scholar
  28. 28.
    Kochetova T, Krylov V, Smolyarchuk M, Sokov D, Lunev A, Shiryaev S, Kruglova O, Makeenkova T, Petrosyan K, Dolgova A, Poluektova M, Galkin V, Kaprin A (2017) 188Re zoledronic acid in the palliative treatment of painful bone metastases. Int J Nucl Medi Res. Google Scholar
  29. 29.
    Erfani M, Rahmani N, Doroudi A, Shafiei M (2017) Preparation and evaluation of rhenium-188-pamidronate as a palliative treatment in bone metastasis. Nucl Med Biol 49:1–7CrossRefGoogle Scholar
  30. 30.
    Janoki GA, Polyak A, Kiraly R, Balogh L, Korosi L, Mathe D (2007) Comparative evaluation of therapeutic radiopharmaceuticals. International Atomic Energy Agency, ViennaGoogle Scholar
  31. 31.
    Erfani M, Doroudi A, Dinari MA, Shirmardi SP (2015) Preparation of a rhenium-188 labeled bisphosphonate for bone pain palliation therapy. J Radioanal Nucl Chem 303:2027–2032Google Scholar
  32. 32.
    Stenbeck G, Horton MA (2000) A new specialized cell-matrix interaction in actively resorbing osteoclasts. J Cell Sci 13:1577–1587Google Scholar
  33. 33.
    Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA (1991) Bisphosphonate action: alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88(6):2095–2105CrossRefGoogle Scholar
  34. 34.
    Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH (2006) Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38(5):617–627CrossRefGoogle Scholar

Copyright information

© Akadémiai Kiadó, Budapest, Hungary 2018

Authors and Affiliations

  • Mostafa Erfani
    • 1
  • Mina Tabatabaei
    • 2
  • Alireza Doroudi
    • 2
  • Mohammad Shafiei
    • 1
  1. 1.Radiation Application Research SchoolNuclear Science and Technology Research Institute (NSTRI)TehranIran
  2. 2.School of PharmacyAhvaz Jundishapur University of Medical SciencesAhvazIran

Personalised recommendations